Integration of survival data from multiple studies.
Ventz S, Mazumder R, Trippa L.
Biometrics. 2021 Jun 30. PMID: 34190337
Associate Professor
Lorenzo Trippa
Overview
I am interested in the development of adaptive clinical trial designs. My research includes the study of algorithms and methodologies for the analysis of data generated by adaptive trials. I am also particularly interested in Bayesian nonparametrics, a great source of modeling opportunity in biomedical applications as well as, both computational and theoretical problems.
Bibliography
KMDATA: a curated database of reconstructed individual patient-level data from 153 oncology clinical trials.
Fell G, Redd RA, Vanderbeek AM, Rahman R, Louv B, McDunn J, Arfè A, Alexander BM, Ventz S, Trippa L.
Database (Oxford). 2021 Jun 26. 2021. PMID: 34169314
The Use of External Control Data for Predictions and Futility Interim Analyses in Clinical Trials.
Ventz S, Comment L, Louv B, Rahman R, Wen PY, Alexander BM, Trippa L.
Neuro Oncol. 2021 Jun 09. PMID: 34106270
Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial.
Tolaney SM, Tayob N, Dang C, Yardley DA, Isakoff SJ, Valero V, Faggen M, Mulvey T, Bose R, Hu J, Weckstein D, Wolff AC, Reeder-Hayes K, Rugo HS, Ramaswamy B, Zuckerman D, Hart L, Gadi VK, Constantine M, Cheng K, Briccetti F, Schneider B, Garrett AM, Marcom K, Albain K, DeFusco P, Tung N, Ardman B, Nanda R, Jankowitz RC, Rimawi M, Abramson V, Pohlmann PR, Van Poznak C, Forero-Torres A, Liu M, Ruddy K, Zheng Y, Rosenberg SM, Gelber RD, Trippa L, Barry W, DeMeo M, Burstein H, Partridge A, Winer EP, Krop I.
J Clin Oncol. 2021 Jul 20. 39(21):2375-2385. PMID: 34077270
Impact of HER2 heterogeneity on treatment response of early-stage HER2-positive breast cancer: phase II neoadjuvant clinical trial of T-DM1 combined with pertuzumab.
Metzger Filho O, Viale G, Stein S, Trippa L, Yardley DA, Mayer IA, Abramson VG, Arteaga CL, Spring LM, Waks AG, Wrabel E, DeMeo MK, Bardia A, Dell'Orto P, Russo L, King TA, Polyak K, Michor F, Winer EP, Krop IE.
Cancer Discov. 2021 May 03. PMID: 33941592
Assessment of Simulated SARS-CoV-2 Infection and Mortality Risk Associated With Radiation Therapy Among Patients in 8 Randomized Clinical Trials.
Tabrizi S, Trippa L, Cagney D, Aizer AA, Tanguturi S, Ventz S, Fell G, Bellon JR, Mamon H, Nguyen PL, D'Amico AV, Haas-Kogan D, Alexander BM, Rahman R.
JAMA Netw Open. 2021 03 01. 4(3):e213304. PMID: 33779742
The effects of releasing early results from ongoing clinical trials.
Ventz S, Bacallado S, Rahman R, Tolaney S, Schoenfeld JD, Alexander BM, Trippa L.
Nat Commun. 2021 02 05. 12(1):801. PMID: 33547324
Rationale and design of the Novel Uses of adaptive Designs to Guide provider Engagement in Electronic Health Records (NUDGE-EHR) pragmatic adaptive randomized trial: a trial protocol.
Lauffenburger JC, Isaac T, Trippa L, Keller P, Robertson T, Glynn RJ, Sequist TD, Kim DH, Fontanet CP, Castonguay EWB, Haff N, Barlev RA, Mahesri M, Gopalakrishnan C, Choudhry NK.
Implement Sci. 2021 Jan 07. 16(1):9. PMID: 33413494
Reply to "Keynote 48: Is it really for everyone?"
Schoenfeld JD, Fell G, Haddad RI, Trippa L.
Oral Oncol. 2021 04. 115:105108. PMID: 33277202
Effect of Eribulin With or Without Pembrolizumab on Progression-Free Survival for Patients With Hormone Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer: A Randomized Clinical Trial.
Tolaney SM, Barroso-Sousa R, Keenan T, Li T, Trippa L, Vaz-Luis I, Wulf G, Spring L, Sinclair NF, Andrews C, Pittenger J, Richardson ET, Dillon D, Lin NU, Overmoyer B, Partridge AH, Van Allen E, Mittendorf EA, Winer EP, Krop IE.
JAMA Oncol. 2020 10 01. 6(10):1598-1605. PMID: 32880602